Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus

Bibliography

• Howard BV. Dietary fat and diabetes: a consensus view. Am J Med 2002;113 (Suppl 9B):38S-40S
   Google Scholar
• Utermann G. The mysteries of lipoprotein(a). Science 1989;246:904-10
   PubMed Web of Science ®Google Scholar
• Scanu AM. Lipoprotein(a): a genetically determined cardiovascular pathogen in search of a function. J Lab Clin Med 1990;116:142-6
   PubMedGoogle Scholar
• Berg K. Molecular genetics and genetic epidemiology of cardiovascular diseases and diabetes. Introductory remarks: risk factor levels and variability. Ann Med 1992;24:343-7
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:57U-66U
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46-57
   PubMed Web of Science ®Google Scholar
• Carlson L, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 1989;226:271-6
   PubMed Web of Science ®Google Scholar
• Elisaf M, Bairaktari E, Nicolaides C, et al. The beneficial effect of tamoxifen on the serum lipoprotein Lp(a) levels:an additional anti-atherogenic property. Anticancer Res 1996;16:2725-8
   PubMed Web of Science ®Google Scholar
• Crook D, Sidhu M, Seed M, et al. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992;92:41-7
   PubMed Web of Science ®Google Scholar
• Maggi FM, Piglionica MR, De Michele L, et al. Bezafibrate lowers elevated plasma levels of fibrinogen and lipoprotein (a) in patients with type IIa and IIb dyslpoproteinaemia. Nutr Metab Cardiovasc Dis 1994;4:215-20
   Web of Science ®Google Scholar
• Mikhailidis DP, Ganotakis ES, Spyropoulos KA, et al. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate of lifestyle advice. Int Angiol 1998;17:225-33
   PubMed Web of Science ®Google Scholar
• Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebocontrolled study of bezafibrate: the St Mary's, Ealing, Northwick Park diabetes cardiovascular disease prevention (SENDCAP) study. Diabetes Care 1998;21:641-8
   PubMed Web of Science ®Google Scholar
• Farish E, Spowart K, Barnes JF, et al. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions. Atherosclerosis 1996;126:77-84
   PubMed Web of Science ®Google Scholar
• Taskinen MR, Puolakka J, Pyörälä T, et al. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol 1996;16:1215-21
   PubMed Web of Science ®Google Scholar
• Kostner GM, Gavish D, Leopold B, et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989;80:1313-19
   PubMed Web of Science ®Google Scholar
• Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein(a). J Clin Pharmacol 1993;33:574-80
   PubMedGoogle Scholar
• Nair DR, Papadakis JA, Jagroop IA, et al. Statins and fibrinogen. Lancet 1998;351:1430
   PubMed Web of Science ®Google Scholar
• Topol EJ. Intensive statin therapy-a sea change in cardiovascular prevention. N Engl J Med 2004;350:1562-4
   PubMed Web of Science ®Google Scholar
• Pyorälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al: CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
   PubMed Web of Science ®Google Scholar
• Rebouche CJ, Paulson DJ. Carnitine metabolism and function in humans. Annu Rev Nutr 1986;6:41-66
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Vacante M, Avitabile T, et al. L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. Am J Clin Nutr 2009;89:71-6
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Calabresi L, Ferrara S, et al. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis 2000;10:247-51
   PubMedGoogle Scholar
• Derosa G, Cicero AF, Gaddi A, et al. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003;25:1429-39
   PubMed Web of Science ®Google Scholar
• Solfrizzi V, Capurso C, Colacicco AM, et al. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. Atherosclerosis 2006;188:455-61
   PubMedGoogle Scholar
• Cain WJ, Millar JS, Himebauch AS, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res 2005;46:2681-91
   PubMed Web of Science ®Google Scholar
• Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 1999;10:225-36
   PubMed Web of Science ®Google Scholar
• Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60
   PubMed Web of Science ®Google Scholar
• Luke MM, Kane JP, Liu DM, et al. A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol 2007;27:2030-6
   PubMedGoogle Scholar
• Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 1993;87:1135-41
   PubMed Web of Science ®Google Scholar
• Devlin CM, Lee SJ, Kuriakose G, et al. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler Thromb Vasc Biol 2005;25:1704-10
   PubMedGoogle Scholar
• Gaubatz JW, Hoogeveen RC, Hoffman AS, et al. Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins. J Lipid Res 2001;42:2058-68
   PubMedGoogle Scholar
• Nassir F, Bonen DK, Davidson NO. Apolipoprotein(a) synthesis and secretion from hepatoma cells is coupled to triglyceride synthesis and secretion. J Biol Chem 1998;273:17793-800
   PubMed Web of Science ®Google Scholar
• Mingrone G, Greco AV, Capristo E, et al. L-carnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr 1999;18:77-82
   PubMed Web of Science ®Google Scholar
• Power RA, Hulver MW, Zhang JY, et al. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 2007;50:824-32
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Vacante M, Motta M, et al. Effect of L-Carnitine on the size of LDL particles in the type 2 diabetic patients treated with simvastatin. Metabolism 2009 In press
   PubMedGoogle Scholar
• Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci USA 1991;88:434-8
   PubMed Web of Science ®Google Scholar
• Van Linthout S, Spillmann F, Riad A, et al. Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation 2008;117:1563-73
   PubMed Web of Science ®Google Scholar
• Mbewu AD, Bhatnagar D, Durrington PN, et al. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 1991;11:940-6
   PubMedGoogle Scholar
• Krempler F, Kostner GM, Roscher A, et al. Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J Clin Invest 1983;71:1431-41
   PubMed Web of Science ®Google Scholar
• Niemeier A, Willnow T, Dieplinger H, et al. Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro. Arterioscler Thromb Vasc Biol 1999;19:552-61
   PubMed Web of Science ®Google Scholar
• März W, Beckmann A, Scharnagl H, et al. Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. FEBS Lett 1993;325:271-5
   PubMed Web of Science ®Google Scholar
• Argraves KM, Kozarsky KF, Fallon JT, et al. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997;100:2170-81
   PubMed Web of Science ®Google Scholar
• Keesler GA, Gabel BR, Devlin CM, et al. The binding activity of the macrophage lipoprotein(a)/apolipoprotein(a) receptor is induced by cholesterol via a post-translational mechanism and recognizes distinct kringle domains on apolipoprotein(a). J Biol Chem 1996;271:32096-104
   PubMedGoogle Scholar